A new crop of evidence — both anecdotal and research based — is pointing to these drugs as a potential option for people ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
It appears not all weight-loss drugs are created equal. The users of one drug report more weight loss comparted to another ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...
With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
The weight loss revolution is in full swing, with the number of patients receiving Wegovy (NVO) having doubled while those ...
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.